Drug
Aducanumab clinical trials
Also written BIIB037 and Aduhelm.
- studies test it
- 12
- open now
- 0
- in phase 3
- 4
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 1
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses aducanumab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) TherapyActive, not recruitingEarly Phase 1Ali RezaiNCT05469009Written as Aducanumab
- A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseTerminatedPhase 3BiogenNCT05310071Written as Aducanumab
- A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205TerminatedPhase 3BiogenNCT04241068Written as Aducanumab
- A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy VolunteersCompletedPhase 1BiogenNCT05216887Written as Aducanumab
- A Study to Assess Absolute Bioavailability of Aducanumab in Healthy VolunteersCompletedPhase 1BiogenNCT04924140Written as Aducanumab
- A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging AbnormalitiesTerminatedPhase 2BiogenNCT03639987Written as Aducanumab
- 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseTerminatedPhase 3BiogenNCT02477800Written as Aducanumab (BIIB037)
- 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseTerminatedPhase 3BiogenNCT02484547Written as Aducanumab (BIIB037)
- Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's DiseaseCompletedPhase 1BiogenNCT02434718Written as Aducanumab
- Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's DiseaseTerminatedPhase 1BiogenNCT01677572Written as Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
- Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy ParticipantsCompletedPhase 1BiogenNCT02782975Written as aducanumab
- Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's DiseaseCompletedPhase 1BiogenNCT01397539Written as BIIB037
As the comparator · 1 — what is tested is compared with aducanumab
Codes
What other systems call aducanumab · ClinicalTrials.gg INT000291
- MeSH (NLM) C000600266aducanumabOne source NLM
- UNII (FDA) 105J35OE21ADUCANUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2557217Confirmed FDA, Wikidata
- Wikidata Q15708278aducanumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166444AducanumabOne source FDA
- DrugBank DB12274One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000600266 | aducanumab | One source NLM |
| UNII (FDA) | 105J35OE21 | ADUCANUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2557217 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708278 | aducanumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166444 | Aducanumab | One source FDA |
| DrugBank | DB12274 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.